Liposome-Based Drug Delivery System Development for Stroke

The bilayer structure allows liposomes to be loaded with hydrophilic or hydrophobic drugs, and the cell-like membrane structure gives them low toxicity, good biocompatibility, and long circulation time. In addition, the surface of liposomes can be modified with polyethylene glycol and targeting ligands, to enable drugs to target specific damaged areas. Currently, liposomal nanoparticles are widely used in the treatment of ischemic stroke. As a drug delivery system, liposomes can allow stroke drugs to cross the blood-brain barrier (BBB). Liposomes also protect stroke drugs from degradation in the biological environment, thereby increasing circulation time and accumulation in target tissues.

Fig. 1. Liposomes as near-perfect drug carriers in ischemic stroke therapy. (Zhang et al., 2024)

Our Liposome-Based Drug Delivery System Development Services

As a leading service provider in the field of stroke, Ace Therapeutics offers comprehensive services to help clients develop and optimize liposomes for stroke drug delivery. Our team of experts consistently delivers high quality solutions.

Surface Engineering of Liposomes for Stroke Drug Delivery

We can modify the structure of liposomes, and conjugate targeting ligands and binding sites onto the surface of liposomes to improve the ability and pharmacokinetics of stroke drugs delivered across the BBB. Our liposome surface modification strategies ensure that stroke drugs are delivered to specific target cells or tissues, thereby reducing side effects.

• Stealth liposome technology: We can add polymers to maintain liposome stability and reduce immunogenicity.
• Ligand strategies: We can attach ligands (e.g. antibodies or aptamers) to the surface of liposomes to increase binding affinity to specific receptors on target cells.
• pH-sensitive liposomes: We can incorporate pH-sensitive components into liposomes to achieve selective release of stroke drugs under acidic conditions in the target tissue.
• Temperature-sensitive liposomes: We use lipids or polymers with phase transition temperatures close to body temperature to allow phase transition or hydrolysis at elevated temperatures to release stroke drugs.

Drug Loading Techniques for Liposome-Based Drug Delivery Systems

Ace Therapeutics offers several methods to incorporate specific neuroprotective agents into liposomes for the treatment of ischemic stroke.

• Passive drug loading methods
• Active drug loading methods

Preclinical Studies of Liposome-Based Drug Delivery System for Stroke

We provide reliable in vitro models of stroke to analyze the effects of liposome-based drug delivery systems.

We provide MCAO models to assess the safety and efficacy of liposomal formulations.

• Trans-BBB PK to analyze the ability of stroke drugs to cross the BBB
• Pharmacokinetic studies of liposomal formulations
• Measurement of cerebral infarct volume
• Behavioral tests

Ace Therapeutics provides reliable strategies for liposome design and drug efficacy data to help clients develop liposome-based drug delivery systems. By partnering with Ace Therapeutics, pharmaceutical companies can accelerate the stroke drug development process. If you are interested in our services, please do not hesitate to contact us!

1. Zhang, Q., et al. (2024). Innovations in Breaking Barriers: Liposomes as near-perfect drug carriers in ischemic stroke therapy. International Journal of Nanomedicine, 3715-3735.